SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-011876
Filing Date
2022-08-03
Accepted
2022-08-03 16:12:41
Documents
64
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nbrv-20220630x10q.htm   iXBRL 10-Q 2036546
2 EX-10.1 nbrv-20220630xex10d1.htm EX-10.1 36194
3 EX-31.1 nbrv-20220630xex31d1.htm EX-31.1 10554
4 EX-31.2 nbrv-20220630xex31d2.htm EX-31.2 11269
5 EX-32.1 nbrv-20220630xex32d1.htm EX-32.1 5750
6 EX-32.2 nbrv-20220630xex32d2.htm EX-32.2 6283
  Complete submission text file 0001558370-22-011876.txt   7116391

Data Files

Seq Description Document Type Size
7 EX-101.SCH nbrv-20220630.xsd EX-101.SCH 57265
8 EX-101.CAL nbrv-20220630_cal.xml EX-101.CAL 43608
9 EX-101.DEF nbrv-20220630_def.xml EX-101.DEF 222255
10 EX-101.LAB nbrv-20220630_lab.xml EX-101.LAB 473877
11 EX-101.PRE nbrv-20220630_pre.xml EX-101.PRE 341161
58 EXTRACTED XBRL INSTANCE DOCUMENT nbrv-20220630x10q_htm.xml XML 982603
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 221132723
SIC: 2834 Pharmaceutical Preparations